Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Radiopharm Theranostics Plans Phase 3 RAD101 Brain Metastases Imaging Trial in Q1 2027

By Public Technologies
  • Radiopharm Theranostics expects to start a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases in the first quarter of 2027.
  • The planned trial follows a successful FDA end-of-Phase 2 meeting in October 2026; previously reported results met the primary endpoint.
  • Interim Phase 2b imaging results supporting Phase 3 development will be presented at the Society for Neuro-Oncology meeting on November 12-15, 2026.
  • Siemens Healthineers will manufacture and distribute RAD101 doses for the US portion of the Phase 3 registrational trial.
  • RAD301 Phase 1 results reported in September 2026 showed favorable safety and tumor uptake in pancreatic cancer, supporting advancement toward Phase 2.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020800PRIMZONEFULLFEED1001301154) on November 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.